Free tool · No account

Clinical trials for colorectal cancer

Colorectal cancer trials increasingly test targeted and immune therapies, some limited to tumors with specific features like MSI-high status or a KRAS/BRAF mutation. A recent genomic report helps narrow the field.

1,545 recruiting trials. Showing a sample.

  • recruitingNANCT06753136

    Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype

    This is an monocenter, single arm, clinical investigation that evaluate the impact of the method on the objective response rate (ORR) of visceral lesions undergoing electrochemotherapy. Electrochemotherapy is a well-defined method for the treatment of cutaneous and subcutaneou...

    Listed by the study for Liver Metastasis Colon Cancer. Record updated 2026-04-13.

    Sponsored by Istituto Oncologico Veneto IRCCSFull details on ClinicalTrials.gov →
  • recruitingPhase 2NCT07469306

    Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer

    To explore the complete response (CR) rate of modified short-course radiotherapy plus CAPOX and Tislelizumab versus Long-course Chemoradiotherapy plus Tislelizumab for locally advanced rectal cancer.

    Listed by the study for Locally Advanced Rectal Cancer. Record updated 2026-10-01.

    Sponsored by Fujian Cancer HospitalFull details on ClinicalTrials.gov →
  • recruitingPhase 1NCT04991948

    Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer

    The purpose of the CYAD-101-002 study is to assess the safety and clinical activity of CYAD-101 in patients with unresectable metastatic colorectal cancer administered concurrently with FOLFOX chemotherapy, followed by pembrolizumab treatment.

    Listed by the study for Unresectable Metastatic Colorectal Cancer. Record updated 2022-03-09.

    Sponsored by Celyad Oncology SAFull details on ClinicalTrials.gov →
  • recruitingNCT07269249

    Real-world Efficacy and Safety of Neoadjuvant Dostarlimab in Patients With dMMR/MSI-H Locally Advanced Rectal Cancer

    This is an observational, retrospective-prospective, multicentre trial enrolling all patients included in the AIFA monitoring registry of Dostarlimab for the indication in rectal cancer. The aims of the study are to describe the clinical outcomes and safety of patients with dM...

    Listed by the study for Locally Advanced Rectal Cancer (LARC). Record updated 2025-12-08.

    Sponsored by National Cancer Institute, NaplesFull details on ClinicalTrials.gov →
  • recruitingNCT07781306

    PrOspEctive Metastases Imaging (POEM)

    This is a non-interventional, observational study with an optional interventional biobanking activity. Liver metastases of patients undergoing partial hepatectomy will be sampled completely while respecting the orientation used for medical imaging, in order to correlate the hi...

    Listed by the study for Colorectal Cancer. Record updated 2026-08-24.

    Sponsored by Cancer Research AntwerpFull details on ClinicalTrials.gov →
  • recruitingNANCT06783244

    Low Versus Standard Intraabdominal Pressure in Robot-assisted Colorectal Cancer Surgery

    The goal of this clinical trial is to investigate the influence of low intraabdominal pressure (compared to standard intraabdominal pressure) during robot-assisted colorectal cancer surgery on patients wellbeing after surgery. Patients included are diagnosed with colon- or rec...

    Listed by the study for Colorectal Cancer. Record updated 2025-04-29.

    Sponsored by Victoria RosbergFull details on ClinicalTrials.gov →
  • recruitingNCT06353854

    Prospective National Cohort Evaluating Predictive Biomarkers of Resistance to Immunotherapy in Patients With MSI/dMMR Metastatic Colorectal Cancer (CORESIM)

    The Keynote 117 phase III trial demonstrated the superiority of pembrolizumab (anti-PD1 monoclonal antibody) versus chemotherapy +/- targeted therapy in first-line treatment of dMMR/MSI metastatic colorectal cancer (mCRC). However, primary resistance to pembrolizumab was obser...

    Listed by the study for Colorectal Cancer Metastatic. Record updated 2025-10-06.

    Sponsored by Federation Francophone de Cancerologie DigestiveFull details on ClinicalTrials.gov →
  • recruitingNANCT06576986

    Effect of Synbiotic Supplementation on the Prevention of Mucositis in Cancer Patients Undergoing Chemotherapy

    Introduction: In the 2023-2025 period, colorectal cancer (CRC) will be the third most common type of cancer in Brazil. The most commonly used therapeutic approaches are chemotherapy (QTx) and radiotherapy (RTx). QTx agents, such as capecitabine, affect both malignant cells and...

    Listed by the study for Colo-rectal Cancer. Record updated 2024-08-29.

    Sponsored by Federal University of Minas GeraisFull details on ClinicalTrials.gov →
  • recruitingPhase 3NCT06951503

    AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer

    This trial is a Phase III study. The purpose of this study is to evaluate the efficacy and safety of AK112 and chemotherapy versus bevacizumab and chemotherapy for the first-line treatment of metastatic colorectal cancer.

    Listed by the study for Colorectal Adenocarcinoma. Record updated 2026-03-04.

  • recruitingPhase 2NCT06245356

    Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer

    The goal of this clinical trial is to test the safety of the trifluridine/tipiracil as replacement of fluoropyrimidines based chemotherapy as first line metastatic colorectal or gastroesophageal cancer regimens in patients with dihydropyrimidine dehydrogenase (DPD) deficiency....

    Listed by the study for Metastatic Colorectal Cancer. Record updated 2025-12-10.

Data from ClinicalTrials.gov, retrieved 2026-11-14. Study sponsors write and update their own records there, including the recruitment status shown here, and the U.S. government does not review or approve every study listed. A trial showing up here is not a recommendation and not a determination that anyone qualifies. Eligibility is decided by the trial's own doctors.

Refine for your situation

Add whatever you know: an age, a city, a mutation from a pathology report. We'll narrow the list to trials that fit. Describe it in your own words.

Whatever you have: the diagnosis, a mutation if you know it, age, where you live.

Trials for other conditions

What we will never do with your records

This generator runs without an account, and KeptWell itself makes the same promises to every family, regardless of plan or price.

We won't sell your data.
Not to advertisers, not to data brokers, not to insurers, not to pharma, not to anyone, in any form, ever.
We won't train AI models on your records.
KeptWell does not opt in to model training. OpenAI and Anthropic do not use API inputs or outputs to train their models by default.
We won't lock you in.
You can export everything in your circle as a ZIP at any time. Cancellation is one click.

Read the full data practices →

Common questions

Is this colorectal cancer trial finder really free?
Yes. You describe the situation, we search ClinicalTrials.gov and show what matches. No account, no payment, no email required. Nothing you type is saved.
Does showing up here mean the patient qualifies?
No. A listing here is not a recommendation, and the U.S. government does not review or approve every study on ClinicalTrials.gov. These are trials worth asking your care team about. Every trial has detailed eligibility criteria that the trial's own doctors evaluate, and many depend on test results and treatment history that only your medical team knows in full.
How current is this list?
The trials come directly from ClinicalTrials.gov and are refreshed daily, with the retrieval date shown under the list. Each study record is written and kept up to date by that study's own sponsor, so the recruitment status is what the sponsor last reported. Each result links to the full, live record, and the finder above always runs a fresh search when you use it.
What should I do with a trial that looks promising?
Bring it to your oncologist or care team, and mention the NCT number (the ID that starts with NCT). They can tell you whether it is a genuine fit and refer you to the trial site.

Found trials worth discussing? Keep them next to the records.

The next step is a conversation with the care team, and that goes better when the scans, labs, and trial details live in one place everyone in the family can see. That's what KeptWell is: the binder, but it understands what's inside.

Get started

We'll email you a secure sign-in link. It works whether you're new here or already have an account.